MALVERN, Pa., June 18, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD), is pleased to announce that it has been selected to present the data from its latest Alzheimer’s study in an extended 45-minute session at the Alzheimer’s Association International Conference® 2024 (AAIC®).

宾夕法尼亚州马尔文（MALVERN），2024年6月18日（环球通讯社）--通过IBN--安诺维斯生物公司（纽约证券交易所：ANVS）（“安诺维斯”或“公司”），一家开发神经退行性疾病新疗法的晚期药物平台公司，如阿尔茨海默病（AD）和帕金森病（PD），很高兴地宣布，它已被选中在2024年阿尔茨海默病协会国际会议（AAIC®）上延长45分钟的会议上展示其最新阿尔茨海默病研究的数据。

The conference will take place from July 28 to August 1 in Philadelphia, USA, and online.Dr. Cheng Fang, Senior VP of Research & Development at Annovis Bio, along with Kathleen A. Welsh-Bohmer, Ph.D., Professor in Psychiatry and Neurology at Duke University, and Maria L. Maccecchini, Ph.D., Founder, President, CEO of Annovis Bio Inc., will deliver a 45-minute oral presentation in a Developing Topics session, highlighting the significant findings from the company’s recent studies of Buntanetap in patients with mild AD.

会议将于7月28日至8月1日在美国费城举行，并在线举行。。

The presentation will also provide an in-depth look at the drug's efficacy and safety in both APOE4 carriers and non-carriers, underscoring its potential as a breakthrough treatment for AD.“We look forward to sharing the details of our Phase 2/3 results with the scientific community at this prominent conference,” said Dr.

该演讲还将深入研究该药物在APOE4携带者和非携带者中的疗效和安全性，强调其作为AD突破性治疗的潜力。“我们期待在这次重要会议上与科学界分享我们的2/3期结果的细节，”Dr。

Cheng Fang, Senior VP of Research & Development at Annovis Bio. “We are also grateful for the 45-minute format, which allows us to present our data comprehensively.”AAIC is a premier global forum for the latest advancements in dementia research, bringing together scientists from around the world to share their findings, discuss new ideas, and foster collaborations.

Annovis Bio研究与开发高级副总裁程芳（Cheng Fang）表示：“我们也很感谢45分钟的格式，它使我们能够全面展示我们的数据。”AAIC是痴呆症研究最新进展的首要全球论坛，汇集了来自世界各地的科学家，分享他们的发现，讨论新想法，并促进合作。

Annovis Bio is honored to contribute to this vital exchange of knowledge and innovation.Details of the Pres.

Annovis Bio很荣幸能为这一重要的知识和创新交流做出贡献。。